Drawing for GELWEAVE LUPIAE

USPTO serial 79144332

GELWEAVE LUPIAE

Reviewed by CopyMark Law Group

Reg. 4838737Status 404
Filing date
Status date
Registration date
Oct 27, 2015
Examiner
MICHELI, ANGELA M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GELWEAVE LUPIAE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Thomas W. Cole

Thomas W. Cole Roberts Mlotkowski Safran & Cole P.C.7918 Jones Branch Drive, Suite 500McLean, VA 22102UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
010Surgical apparatus and instruments for treating cardiovascular disease; medical apparatus and instruments for treating cardiovascular disease; prosthetic vascular grafts, prosthetic endovascular grafts, stents, and vascular prostheses; prosthetic vascular woven grafts; surgical implants comprising prosthetic materials; suture materials; patches for repair and reconstruction of internal tissue, namely, cardiovascular patches, pericardial patches, and carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; implantable medical systems, namely, cardiac valves for surgical prostheses, stents, prosthetic vascular grafts, vascular prostheses, prosthetic vascular grafts, prosthetic endovascular grafts, and catheters; implantable medical devices, namely, implants consisting of prosthetic materials, synthetic vascular prostheses, prosthetic vascular grafts, and synthetic heart valve conduits; prosthetic vascular grafts; prosthetic endovascular grafts; surgical graft materials, namely, prosthetic vascular grafts, vascular prostheses for the treatment of aneurysmal or occlusive arterial disease; medical devices for use in endovascular procedures, namely, medical devices for use in treating cardiovascular disease; thoracic stents; synthetic thoracic stent grafts; synthetic stent grafts; synthetic stent graft systems comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems comprising more than one component comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems and devices comprising components of more than one stent graft comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems and devices comprising components of more than one type of stent graft comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; thoracic synthetic stent graft systems comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; thoracic stent graft devices; prosthetic systemic vascular grafts; prosthetic vascular straight grafts; prosthetic vascular abdominal grafts; prosthetic vascular thoracic grafts; prosthetic vascular branched grafts; prosthetic vascular pre-curved grafts; prosthetic vascular aortic arch grafts; prosthetic vascular branched arch grafts; delivery systems for synthetic stent graft systems comprised of medical instruments for intraluminal emplacement of stents or of synthetic stent grafts, namely, stent or synthetic stent graft delivery systems; aneurysm repair systems comprised of catheter delivered stent grafts, medical instruments for intraluminal emplacement of stents or stent systems or of synthetic stent grafts, namely, stent delivery systems or stent graft delivery systems or synthetic stent graft delivery systems; cardiac valves for surgical prostheses; cardiac valve replacement systems, namely, prosthetic cardiac valves; heart valves, namely, prosthetic heart valves; heart valve conduits, namely, catheters for implanting heart valves; cardiac patches, namely, cardiovascular patches, pericardial patches, and carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; vascular patches, namely, cardiovascular patches, pericardial patches, and carotid patches, namely, namely, surgical mesh comprised primarily of prosthetic materials; parts and fittings for all of the aforementioned goodsSECTION 71 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 3, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Aug 3, 2024DETHDEATH OF INTERNATIONAL REGISTRATION
Mar 20, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB
Mar 1, 2023INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 1, 2023INPCINVALIDATION PROCESSED
Jan 13, 2023INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED
May 13, 2022C71TCANCELLED SECTION 71
Oct 27, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 8, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Apr 28, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB
Apr 28, 2016FIMPFINAL DISPOSITION PROCESSED
Jan 27, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 27, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 18, 2015OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 2, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 2, 2015OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 11, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 11, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 7, 2015GPNXNOTIFICATION PROCESSED BY IB
Jul 22, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 22, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 22, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 4, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 2, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 2, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 2, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 25, 2015ALIEASSIGNED TO LIE
Jun 19, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 5, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 17, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Apr 16, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 16, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 17, 2014GNFNNOTIFICATION OF FINAL REFUSAL EMAILED
Oct 17, 2014GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 17, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 29, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 29, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 24, 2014TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 24, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 23, 2014RFNTREFUSAL PROCESSED BY IB
May 1, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 30, 2014RFRRREFUSAL PROCESSED BY MPU
Apr 30, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 29, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2014DOCKASSIGNED TO EXAMINER
Apr 1, 2014MAFRAPPLICATION FILING RECEIPT MAILED
Mar 28, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 27, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance